Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 27;6(1):285.
doi: 10.1038/s41392-021-00695-0.

Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C

Zhongcheng Zhou #  1 , Peng Du #  1 , Meixing Yu  1 , Daniel T Baptista-Hon  2 , Man Miao  2 , Andy P Xiang  3 , Johnson Yiu-Nam Lau  4 ; COVID-19 Immunity Investigation Group; Gen Li  5 , Kang Zhang  6   7   8
Collaborators, Affiliations
Comment

Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C

Zhongcheng Zhou et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. K.Z. is one of the Editors-in-Chief of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.

Figures

Fig. 1
Fig. 1
Infectivity and neutralizing activities of immune sera for CAL.20C variants. a Infectivity levels with a pseudotyped virus. X-axis shows different COVID-19 S variants and Y-axis shows relative luminescence unit determined by infectivity assay (compared to the cell culture control). b Comparison between the binding affinity of RBD and RBD (L452R) with immune sera from nonhuman primates by ELISA (n = 6). c Comparison between the binding affinity of S1 (D614G) and S1 (W152C-L452R-D614G) with immune sera from nonhuman primates by ELISA (n = 6). d Neutralization activities of the immune sera from nonhuman primates vaccinated with an RBD protein vaccine (n = 6). e Neutralization activities of sera from COVID-19 infection convalescent patients against various pseudotyped viruses expressing COVID-19 S variants related to CAL.20C (n = 11). f Neutralization activities of sera from vaccine recipients (n = 8, Pfizer-BioNTech) against various pseudotyped viruses expressing COVID-19 S variants related to CAL.20C. g Cross-comparison of neutralization activities of sera from the RBD-vaccinated monkeys (n = 6), COVID-19 convalescent patients (n = 11), and mRNA vaccine recipients (n = 8, Pfizer-BioNTech) against various pseudotyped viruses expressing COVID-19 S variants related to CAL.20C. In b–g, X-axis shows different COVID-19 S variants and Y-axis shows ED50 or lg(ED50), values of serial dilution for 50% effective neutralization. n.s. nonsignificant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001
See this image and copyright information in PMC

Comment on

References

    1. Wang C, et al. COVID-19 in early 2021: current status and looking forward. Signal Transduct. Target Ther. 2021;6:114. doi: 10.1038/s41392-021-00527-1. - DOI - PMC - PubMed
    1. Yang J, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586:572–577. doi: 10.1038/s41586-020-2599-8. - DOI - PubMed
    1. Korber B, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827.e19. doi: 10.1016/j.cell.2020.06.043. - DOI - PMC - PubMed
    1. Deng X, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184:3426–3437. doi: 10.1016/j.cell.2021.04.025. - DOI - PMC - PubMed
    1. Garcia-Beltran WF, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383.e2379. doi: 10.1016/j.cell.2021.03.013. - DOI - PMC - PubMed